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Abstract 
KRAS is a small GTPase that regulates cell proliferation and survival. In tumors, the KRAS 
gene is mutated, and leading to unregulated tumor growth. Despite the recognized importance 
of KRAS in cancer, attempts to develop small molecule inhibitors have proved unsuccessful. 
An alternative strategy is gene silencing and the use of small nucleic acid sequences (e.g. 
siRNA, shRNA), has been reported to successfully downregulate KRAS. In this study we 
developed ternary nanocomplexes to deliver an anti-KRAS siRNA to colorectal cancer cells, 
exploiting the interaction of hyaluronic acid (HA) with CD44 as a means to achieve selective 
targeting of CD44-positive cancer cells. Two different polycations, poly(hexamethylene 
biguanide) and chitosan, were complexed with siRNA and coated with HA. Physico-chemical 
properties and stability of nanoparticles were characterized, including size, surface charge, 
and degree of siRNA protection. We demonstrate nanoparticle internalization (flow 
cytometry), siRNA cytosolic release (confocal microscopy) and KRAS silencing (RT-qPCR) 
in CD44+/KRAS+ colorectal cancer cell line, HCT-116. Further we demonstrate that the 
uptake of HA-decorated nanoparticles in cancer cells is higher when co-cultured with 
fibroblasts. 
 
 
 
Graphical abstract  
 
  
 3 
1. Introduction 1 
KRAS is a small GTPase involved in the regulation of numerous cellular processes, including 2 
growth, proliferation, survival and other aspects of cellular biology accordingly to its 3 
active/inactive state (Ellis and Clark, 2000). KRAS mutations impair the ability of the KRAS 4 
protein to switch between states, hence mutated KRAS acquires oncogenic properties; such 5 
mutations are observed in approximately 30% of tumors. In particular, pancreatic and 6 
colorectal cancers (Cox et al., 2014; Ross et al., 2017; Stephen et al., 2014), are involved in 7 
tumor initiation and maintenance (Chin et al., 1999; Collins et al., 2012; Zhang et al., 2006) 8 
and are associated with poor prognosis and increased resistance to treatment, including 9 
targeted therapies (e.g. EGFR-TKIs (Überall et al., 2008)). Therefore, it is not surprising that 10 
KRAS is considered an attractive target, but unfortunately an elusive one, since its 11 
intracellular location (Blasco et al., 2011) and very low concentration make its selective 12 
inhibition very challenging. To date, probably the most successful approach has employed 13 
farnesyl transferase inhibitors (KRAS activation requires post-translational farnesylation), 14 
and the use of small molecules to block mutant KRAS and RAS family protein and their 15 
downstream effectors have been developed or are under clinical trial studies (Appels et al., 16 
2005; Asati et al., 2017; Shin et al., 2018; Wang et al., 2013). Alternatively, small interfering 17 
RNA (siRNA) has been employed to target KRAS (Collisson et al., 2012; Hatzivassiliou et 18 
al., 2013; Kamerkar et al., 2017; Ross et al., 2017), with some systems translated to up to 19 
phase III trials for the intra-tumoral delivery of siRNA to downregulate KRAS, and reduce 20 
KRAS activity in pancreatic tumors (Zorde Khvalevsky et al., 2013).  21 
Recently, it has been shown that the regulation of KRAS-mediated signaling in lung 22 
adenocarcinoma is strongly linked to CD44 expression (Zhao et al., 2013): interestingly, 23 
CD44 is both a diagnostic/prognostic marker [16] and a targetable internalization receptor 24 
[15], hence this association may open the way to more selective KRAS-targeted treatments. 25 
In both its standard and higher molecular weight variant isoforms (CD44v2-v10), CD44 has a 26 
major role as a cell surface receptor for hyaluronic acid (HA) (Mattheolabakis et al., 2015; 27 
Ponta et al., 2003) responsible for both its recognition, binding and internalization (Culty et 28 
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al., 1992). In tumors, CD44 is often expressed as its higher molecular weight variant 29 
isoforms, known to alter cellular behavior and signaling pathways (Culty et al., 1992; Misra 30 
et al., 2008). The variant isoform CD44v6 is of particular interest: it is not only expressed 31 
when tumor associated fibroblasts are activated, but also triggers receptor kinase activities 32 
suggesting again a correlation between CD44 and KRAS in adenocarcinomas (Kim et al., 33 
1994; Misra et al., 2011). Unsurprisingly, HA has been widely employed in the context of 34 
CD44-targeting therapies, e.g. to improve water solubility or overcome drug resistance 35 
(Auzenne et al., 2007; Coradini et al., 1999; Luo et al., 2002; Yi Luo et al., 2000), with some 36 
successful cases currently in clinical trials (Bassi et al., 2011; Rios de la Rosa et al., 2018). 37 
We are specifically interested in HA-presenting colloidal carriers, which include liposomes 38 
(Surace et al., 2009), solid nanoparticles (Li et al., 2013; Ma et al., 2012; Yu et al., 2013), or 39 
self-assembly nano-systems (Ganesh et al., 2013; Janes et al., 2001; Lallana et al., 2017). 40 
These systems in principle, combine CD44 targeting and CD44-mediated internalization with 41 
the Enhanced Permeation and Retention (EPR) effect (Stylianopoulos and Jain, 2015), which 42 
can further help the selectivity of a targeted therapy. 43 
Optimal therapeutic strategies should specifically target the mutated KRAS gene and have 44 
minimal systemic toxicity. To improve the selectivity and delivery of anticancer therapeutics, 45 
an effective strategy may require target-ligand interactions and formulation of nanoparticles 46 
able to promote internalization and cargo release at the desired intracellular site to effectively 47 
address the clinical translation aspects (Birzele et al., 2015; Karousou et al., 2017; Rios de la 48 
Rosa et al., 2017a). One strategy that our group and others have explored over the past decade 49 
is the use of HA-decorated nanoparticles in order to deliver nucleic acid via CD44-HA 50 
interactions. HA provides stability, low protein adsorption and CD44-targeting to the 51 
nanoparticles, which include also a polycation that binds both to HA and the payload 52 
(‘glueing’ together the carrier) and would then be responsible for endosomal disruption 53 
typically through the ‘proton sponge’ mechanism (Almalik et al., 2013b; Deng et al., 2014; 54 
Lallana et al., 2017; Parajó et al., 2010). A critical attribute for such systems is indeed the 55 
nature of the polycation, which impacts dramatically on the transfection efficiency. Chitosan; 56 
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for example, requires a careful optimization of molecular weight and degree of acetylation to 57 
achieve effective siRNA delivery (Lallana et al., 2017). In the context of achieving a CD44-58 
mediated KRAS silencing therapy, we here investigated the influence of two main descriptors 59 
of the polycation performance, i.e. size and charge density. To enable this, we prepared a 60 
range of nanoparticles employing high molecular weight chitosan and low molecular weight 61 
poly(hexamethylene biguanide), commercially known as Nanocin (Chindera et al., 2016). The 62 
two respectively act as a very large, poorly charged polycation, and as a very small, densely 63 
charged one. Nanoparticles with anti-KRAS siRNA were obtained via combination of 64 
chitosan or Nanocin and HA coating and compared investigating nanoparticles: 65 
stability/efficacy in the presence of RNases and after storage, ability to deliver siRNA in 66 
CD44+ tumor cells (colorectal cancer cell line HCT-116), and reduction in KRAS expression. 67 
We further investigated the potential of selective delivery of HA-decorated nanoparticles to 68 
cancer cells (HCT-116: CD44+, CD44v6high) when the latter were co-cultured with CD44low 69 
fibroblasts (HDFa). 70 
 71 
2. Materials and Methods 72 
2.1 Nanoparticles and siRNA loading 73 
2.1.1 Material preparation. All materials used in this study were handled under RNase free 74 
conditions: solutions were prepared with nuclease-free solvents, and materials were either 75 
purchased RNase free or made RNase free by sequential washing with RNaseZap® RNase 76 
Decontamination Solution (Ambion, LifeTechnologies, UK), 70% v/v EtOH in water, and 77 
finally sterile nuclease-free water (Ambion, Life Technologies, UK) prior to use. Both 78 
polymeric nanotechnologies were manufactured under controlled mixing conditions using 79 
round-bottom vials (2 mL Safe-Lock Tubes, 2 mL, round bottom, PCR clean, Eppendorf, 80 
UK) and magnetic stirring bars (micro 7 mm × 2 mm, Fisher Scientific, UK). Polycations: 81 
Chitosan from crab shells with viscosity average molecular weight of 656 kDa (Almalik et al., 82 
2013a), was purchased from Sigma Aldrich (Basingstoke, UK; Product code: 51009219, 83 
Lot#WE44069811), and purified prior to use as described elsewhere (Mao et al., 2004). 84 
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Poly(hexamethylene biguanide), also known as polyhexanide and as Nanocin, with average 85 
molecular weight approximately of 3.2 kDa (www.tecrea.com) was prepared as a sterile 86 
solution with a concentration of 1 mg/mL in RNase free water. Hyaluronic acid (HA) with 87 
weight average molecular weight of 183 kDa (GPC with SLS, viscometer and RI detectors) 88 
was purchased from Contipro (Czech Republic). Selected anti-KRAS sequence (siRNA): 1 89 
mg/mL stock solutions of siRNA were prepared in RNase-free water for both L3-siRNA 90 
(sense 5’-3’: GGACUCUGAAGAUGUACCU[dT][dT] 21nt, standard purification, Sigma-91 
Aldrich, UK) and DY547-labeled L3-siRNA (5’-DY547 GGACUCUGAAGAUGUACCU-92 
3’, Dharmacon, UK). Polymeric solutions used for the manufacturing of nanoparticles were 93 
prepared as follows. Chitosan was dissolved overnight at a concentration of 0.69 mg/mL in 94 
4.6 mM HCl (aq) in nuclease-free water and then pH adjusted to 5 by adding nuclease-free 95 
0.1 M NaOH (aq). Chitosan solution was sterile filtered using 0.45 μm PDVF syringe filters. 96 
Nanocin sterile solution was diluted to 0.69 mg/mL with RNase free sterile water. HA was 97 
dissolved overnight in RNase free water at a concentration of 1.5 mg/mL, and then the pH 98 
was adjusted to 5 by adding nuclease-free 0.1 M HCl (aq). HA solution was sterile filtered 99 
using 0.22 μm PES syringe filters. HA solutions with different concentrations were obtained 100 
by diluting the 1.5 mg/mL solution in nuclease-free water. Sterile siRNA solutions were 101 
prepared at the desired concentration by diluting the 100 μM stock solution (aq) with RNase 102 
free and sterile water and stored at -20°C until use. 103 
 104 
2.1.2 Preparation of nanoparticles. HA-coated nanoparticles were prepared with a 105 
concentration of 1 mg/mL in water, using a procedure similar to the one already described by 106 
Lallana et al. (Lallana et al., 2017) for the preparation of RNA-loaded HA/chitosan ternary 107 
complexes. In a typical procedure, a given volume of the 0.69 mg/mL polycation (chitosan or 108 
Nanocin) solution was gently pipetted over the same volume of the siRNA solution (with 109 
concentration adjusted the targeted % wt. loading) under magnetic stirring (1,000 rpm, 25°C). 110 
After 20 min, the polycation/siRNA complex dispersion was gently pipetted to the same 111 
volume of a 1.5 mg/mL HA solution under magnetic stirring (1,000 rpm, 25°C). The final 112 
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mixture was stirred for further 30 min to obtain siRNA-loaded nanoparticle formulations of 113 
ca. 1 mg/mL (calculated from the nanoparticle polyelectrolyte feed ratio). A typical loading 114 
of 2.3% wt. siRNA (compared to the polycation) was used for nanoparticle characterization 115 
and cell culture experiments. Please note that from now the term nanoparticles (NP) refers to 116 
both HA-coated Nanocin or chitosan nanoparticles. 117 
 118 
2.1.3 Preparation of nanoparticles varying polycation:HA ratio. NP were prepared varying 119 
polycation:HA ratio to identify the optimal formulation in terms of size and ζ potential. NP 120 
were prepared using HA solutions with the following concentration (polycation:HA ratio): 121 
0.375 mg/mL (1:1), 0.75 mg/mL (1:2), 1.125 mg/mL (1:3) and 1.5 mg/mL (1:4). For 122 
uncoated NP (1:0 ratio), RNase free water (pH adjusted to 5) was used. NP were prepared 123 
using the same procedure described above (Section 2.1.2). Briefly, the polycation/siRNA 124 
complex dispersion was pipetted in an equivalent volume of HA at different concentrations to 125 
vary the polycation:HA weight ratio. Note that in this case the final concentration of NP 126 
varies from 0.35 mg/mL (1:0) to 1 mg/mL (1:4). 127 
 128 
2.1.4 Preparation of nanoparticles varying siRNA loading. NP were prepared by loading 129 
different amount of siRNA, i.e. 2.3% wt., 25% wt. weight ratio compared to polycation 130 
content. siRNA solutions were prepared in RNase free and sterile water at different 131 
concentrations, 0.016 mg/mL (2.3% wt.) and 0.172 mg/mL (25% wt.). NP were prepared as 132 
described above (Section 2.1.2).  133 
2.2 Nanoparticle characterization 134 
2.2.1 Dynamic Light Scattering (DLS). NP (1mg/mL in water) hydrodynamic diameter (Z-135 
average size), size polydispersity (PDI), and ζ potential were measured at 25°C (pre-136 
equilibration for 2 min; 1 mg/mL) using a Zetasizer Nano ZS (model ZEN3600, Malvern 137 
Instruments Ltd., UK) equipped with a solid state HeNe laser (λ = 633 nm) at a scattering 138 
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angle of 173°. Size distributions were calculated by applying the general-purpose algorithm 139 
and are presented as the average of the Z-average values of three independent samples. 140 
 141 
2.2.2 Payload protection against RNAse. NP (1mg/mL in water) used in this study were 142 
prepared by loading an amount of siRNA corresponding to 25%wt. of the polycation (13 μM 143 
siRNA solution) -/+ HA coating. Briefly, 50 μL of NP were incubated with 50 μL of a 144 
solution of RNase I (AM2294, Ambion, Thermofisher Scientific) (15 mM Tris buffer, 0.3 M 145 
NaCl, pH 7.0) at a concentration of 0, 0.33, and 3.33 U (corresponding to 0, 0.1, 1 and 10 U 146 
of RNase I/mL, respectively). Samples were incubated at 37°C for 30 min. The nuclease 147 
reaction was then quenched with the addition of 7.6 μL of 1.0% SDS (aq). Afterward, 3 μL of 148 
chitosanase (0.066 U/μL, 50 mM acetate buffer, pH 5.0) was added to the mixture, and the 149 
enzymatic reaction was allowed to occur for 3 h at 37°C. Finally, 4.7 μL of a solution of 150 
heparin (80 mg/mL in RNase-free water; corresponding approximately to a negative/positive 151 
charge molar ratio of of 250) was added. The resulting mixture was incubated overnight at 152 
25°C. After centrifugation (13,000 rpm, 30 min), the nucleic acid released in solution was 153 
quantified using polyacrylamide gel electrophoresis (siRNA; 18-well/30 μL, 15% Criterion 154 
TBE-Urea Gel, Biorad; 70 min, 120 V). Gels were finally incubated for 30 min in a 1X 155 
GelRedTM solution and imaged using a UV trans-illuminator (Biorad). 156 
 157 
2.2.3 Nanoparticle stability. NP were stored at 4°C for one week and then tested to check 158 
variations in size, surface charge and efficacy (for silencing experiments details refer to 159 
section 2.7). 160 
2.3 Cell culture and CD44 characterization 161 
2.3.1 General cell culture. All cell culture experiments and following procedures were 162 
performed at the University of Manchester (UK), unless otherwise specified. The human 163 
colorectal carcinoma cell line HCT-116 (CCL-247) was purchased from ATCC (Manassas, 164 
VA, USA) and the adult human dermal fibroblast (HDFa, #C0135C) cell line was purchased 165 
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from Thermo-Fisher Scientific (UK). Cells were cultured in a humidified 5% (v/v) CO2 air 166 
atmosphere at 37°C in complete medium, cell culture growth media were supplemented with 167 
10% (v/v) fetal bovine serum (FBS, F7524), 2 mM L-glutamine (G7513) and 1% (v/v) 168 
penicillin−streptomycin (P4333). McCoy’s 5A medium (M8403) and DMEM (D5671) were 169 
used for HCT-116 and HDFa, respectively. Please note that cells were regularly tested for 170 
mycoplasma and used at passage numbers below 20, and that all cell culture products were 171 
purchased from Sigma- Aldrich (Gillingham, UK). 172 
 173 
2.3.2 CD44 expression: flow cytometry. Cells were grown in T-75 flasks until reaching ~70% 174 
confluency and harvested using pre-warmed Enzyme-Free, Phosphate Buffer solution (PBS)-175 
based Cell Dissociation Buffer (#13151-014, Gibco®/Invitrogen, UK). Individual cell 176 
samples were prepared in 1.5 mL Eppendorf tubes by suspending approximately 100,000 177 
viable cells in 100 μL Fluorescence-Activated Cell Sorting (FACS) buffer (PBS, 5% (v/v) 178 
FBS, 0.1% (m/v) NaN3) and stained for 30 min at room temperature with the primary 179 
antibody mouse anti-human CD44 (1:100) (156-3C11, Cell Signalling Technology, UK) or 180 
IgG1/IgG2 control (1:10) (AbD Serotec, UK). Excess primary antibody was removed by 181 
centrifugation and cells were incubated for further 30 min at room temperature with the 182 
secondary antibody: goat anti-mouse IgG H&L, AlexaFluor®647-conjugated (1:2000) 183 
(ab150115, Abcam, UK). The expression of total CD44 (CD44pan) was recorded for 10,000 184 
live, individual cells using a BD LSRFortessa cytometer (BD Bioscience, San Jose CA, USA) 185 
equipped with the FACSDiva software (v8.0.1). Data were analyzed with FlowJo (vX.0.7, 186 
Tree Star, Ashland, OR, USA) after gating live cells in the FSC/SSC window and cell singlets 187 
in the FSC-H/FSC-A window, respectively. The median fluorescence intensity (MFI) of the 188 
isotype control for each cell line was used to calculate the MFI fold change for each marker. 189 
 190 
2.3.3 CD44 expression: immunofluorescence staining. HCT-116 cells were plated in Ibidi μ-191 
slide (prod.no. 80826, Ibidi®, Germany) at 70% of confluency (approx. 8,000 cells, 37°C, 5% 192 
CO2) and left adhere overnight. Live cells were then stained with the following primary 193 
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antibodies: i) mouse anti-human CD44 (1:100) (156-3C11, Cell Signaling Technology, UK), 194 
ii) mouse anti-human CD44v3 (1:20) (Clone #3G5, R&D Systems, UK), iii) mouse anti-195 
human CD44v6 (1:20) (Clone #2F10, R&D Systems, UK); hence detecting only membrane 196 
bound CD44. Briefly, cells were washed with PBS, incubated with mouse anti-human CD44 197 
primary antibody solutions diluted in 1% (w/v) BSA/PBS on ice for 30 min, gently washed 198 
with PBS, and incubated with 1:250 goat anti-mouse IgG H&L, AlexaFluor®488-conjugated 199 
(ab150117, Abcam, UK) on ice for additional 30 min. Cells were finally washed with PBS 200 
(twice), fixed with 4% PFA solution (5 min, RT), washed with PBS and stored in 1 mg/mL 201 
ascorbic acid solution in PBS at 4°C in the dark until further use. 202 
2.4 Nanoparticle internalization 203 
NP (0.125 mg/mL, final concentration) for cell experiments were prepared in complete cell 204 
growth medium as follows, a final siRNA concentration of 40 nM (0.5 µg/mL) was obtained. 205 
HA-coated chitosan NP (1 mg/mL in water) were diluted after preparation to a concentration 206 
of 250 µg/mL with sterile and nuclease-free water. The final concentration of 125 µg/mL 207 
used for cell culture experiment was obtained by addition of an equal volume of two-fold cell 208 
culture medium (refer to Supporting Information SI.1 for the preparation of concentrated cell 209 
culture medium). Nanocin/HA NP (1 mg/mL) were diluted after preparation by adding 11.6 210 
µL of nanoparticles to complete cell culture media to a final volume of 1 mL. Note that 211 
kinetic of internalization studies were performed loading DY547-siRNA (L3 sequence: 5’- 212 
DY547 GGACUCUGAAGAUGUACCU-3’; Dharmacon, UK) in NP (i.e. DY547-NP). 213 
 214 
2.4.1 Quantification of nanoparticle internalization: flow cytometry. Cells were plated in 215 
Costar tissue culture polystyrene (TCP) 12-well plates with flat bottom (#3513, Corning, UK) 216 
and incubated (37°C, 5% CO2) with 125 µg/mL DY547-NP for specific time points: 4, 12, 217 
and 24 h. Untreated cells were used as a negative control. After each incubation time, 218 
nanoparticle-containing medium was removed, cells were washed with PBS (n=3) and 219 
detached using Trypsin-EDTA solution (#59417C, Sigma-Aldrich, UK) for 10 min at room 220 
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temperature. Trypsin was used to remove any residual membrane-bound nanoparticle, 221 
enabling the detection of internalized nanoparticles exclusively (Rios de la Rosa et al., 222 
2017b). Cells were pelleted (1000 rpm, 5 min, 25°C) and re-suspended in 400 µL PBS. The 223 
internalization of DY547-NP was determined on 10,000 individual and live cells with the BD 224 
LSRFortessa cytometer (BD Bioscience, San Jose CA, USA) equipped with the FACSDiva 225 
software (v8.0.1). Data were analyzed with FlowJo (vX.0.7, Tree Star, Ashland, OR, USA) 226 
after gating single and live events in the FSC-A/FSC-H and FSC/SSC windows, respectively. 227 
Untreated cells were used as autofluorescence control in order to calculate the median 228 
fluorescence intensity (MFI) fold change over time, as well as the percentage of positive 229 
events for each cell line. 230 
 231 
2.4.2 Nanoparticle late endosome/lysosome escape: confocal microscopy. HCT-116 cells 232 
were plated in Ibidi μ-slide (prod.no. 80826, Ibidi®, Germany) at 70% of confluency and left 233 
adhere overnight (37°C, 5% CO2). A volume of 100 µL of DY547-NP (125 µg/mL in 234 
complete cell culture media) was added to each well and cells were incubated for 1 h (37°C, 235 
5% CO2), DY547-NP containing medium was then removed, cells were gently washed with 236 
PBS (n=2) and co-incubated with 100 nM Lysotracker Green (L7526, Invitrogen, Thermo 237 
Fisher, UK) and 1 µM Hoechst (33342, Invitrogen, Thermo Fisher, UK) solution (37°C, 5% 238 
CO2, 10 min). Cells were finally gently washed with PBS (n=2), kept in 1 mg/mL ascorbic 239 
acid solution in PBS and immediately imaged with laser scanning confocal microscope. 240 
 241 
2.4.3 Nanoparticle uptake and role of HA-coating: confocal microscopy. HCT-116 cells were 242 
plated in Ibidi μ-slide (prod.no. 80826, Ibidi®, Germany) at 70% of confluency and left 243 
adhere overnight (37°C, 5% CO2). HA-coated and uncoated DY547-NP (125 µg/mL in 244 
complete cell culture media) were used. A volume of 100 µL of DY547-NP was added to 245 
each well and cells were incubated for 24 h (37°C, 5% CO2), nanoparticle-containing medium 246 
was then removed, cells were gently washed with PBS (n=2), incubated (37°C, 5% CO2, 10 247 
min) with 1 µM Hoechst solution in PBS (33342, Invitrogen, Thermo Fisher, UK), cells were 248 
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gently washed with PBS (n=2), kept in 1 mg/mL ascorbic acid solution in PBS and 249 
immediately imaged with laser scanning confocal microscope. 250 
2.5 Co-culture experiments: HCT-116 and fibroblasts 251 
Co-culture experiments were performed using TCP 6-well plates with flat bottom (Prod. No. 252 
3513, Corning, UK). HCT-116 cells were seeded at a density of 10,000 cells/cm2 on the 253 
bottom of the wells, whereas fibroblasts (HDFa) were seeded on transwell inserts (MW6 254 
Transwell Inserts, 0.4µm PET Membrane, Corning, UK) at a density of 10,000 cells/cm2. 255 
Cells were left adhere for 12 h in separate multi-well plates (37°C, 5% CO2), then inserts 256 
culturing HDFa cells were transferred to the 6-well plates culturing cancer cells and 3 mL of 257 
complete DMEM was added in each well to allow media exchange between the two 258 
compartments (overnight, 37°C, 5% CO2). Cells were co-cultured up to 48 hours (37°C, 5% 259 
CO2). 260 
 261 
2.5.1 Nanoparticle kinetics of internalization in co-culture: flow cytometry. Cells were 262 
incubated with DY547-NP (125 µg/mL in complete cell culture media) corresponding to a 263 
final 40 nM siRNA concentration, up to 48 hours (37°C, 5% CO2). After each time point (4, 264 
12, 24 and 48 h), NP containing medium was removed, cells were washed with PBS (n=3) 265 
and detached using Trypsin-EDTA solution (#59417C, Sigma-Aldrich, UK) for 10 min at 266 
room temperature. Note that trypsin was used to remove any residual membrane-bound 267 
nanoparticle, enabling the detection of internalized DY547-NP only. Cells were pelleted 268 
(1000 rpm, 5 min, 25°C) and re-suspended in 400 µL PBS. The internalization of DY547-NP 269 
was determined on 10,000 individual and live cells with the BD LSRFortessa cytometer (BD 270 
Bioscience, San Jose CA, USA) equipped with the FACSDiva software (v8.0.1). Data were 271 
analyzed with FlowJo (vX.0.7, Tree Star, Ashland, OR, USA) after gating single and live 272 
events in the FSC-A/FSC-H and FSC/SSC windows, respectively. Untreated cells were used 273 
as autofluorescence control in order to calculate the median fluorescence intensity (MFI) fold 274 
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change over time, as well as the percentage of positive events for each cell line. Untreated 275 
cells were also used as a control. 276 
2.6 Imaging: CD44, nanoparticle internalization and siRNA localization 277 
2.6.1 CD44 expression: inverted microscope. Images of IF samples were acquired using an 278 
inverted microscope (Leica DMI6000B, Leica Microsystems, UK) coupled with a 5.5 Neo 279 
sCMOS camera (Andor, UK) and the EL6000 fluorescent lamp (Leica Microsystem, UK), all 280 
controlled by μManager software (v.1.46, Vale Lab, UCSF, USA). For acquisitions, 281 
immersion oil 63X/1.40-0.60 HC PL Apo objective was used, using I3 filter cube (Leica 282 
Microsystem, UK). Images were post-processed using ImageJ adjusting brightness/contrast 283 
for a better visualization of CD44 (v1.51h, http://imagej.nih.gov/ij). 284 
 285 
2.6.2 Nanoparticle internalization: confocal microscope. An inverted SP5 laser scanning 286 
confocal microscope (Leica TSC SP5 AOBS, Leica Microsystem, UK) was used to acquire 287 
volumetric datasets of IF stained cells. Acquisitions were performed using the immersion oil 288 
63X/1.40 HCX PL Apo objective. Images were acquired with sequential scan using 405, 488, 289 
546 and 594 nm laser lines. Images were acquired with different settings accordingly to each 290 
experiment, in particular pinhole was kept to 1 airy unit aperture, pixel size adjusted to 150-291 
165 nm, laser lines settings were adjusted to the dyes, frequency scan and averaged line were 292 
modified accordingly to the sample, whether live or fixed. Images were post-processed using 293 
ImageJ adjusting brightness/contrast for a better visualization of components (v1.51h, 294 
http://imagej.nih.gov/ij). Large field images were also used to quantify the amount of siRNA 295 
internalized: briefly, the maximum projection of the siRNA channel was obtained, Otsu 296 
threshold was applied, the area of the signal was measured and expressed as % with respect to 297 
the scanned area.  298 
2.7 siRNA delivery and KRAS silencing  299 
NP (0.125 mg/mL, final concentration in complete cell culture media) were used for KRAS 300 
silencing experiments. NP were prepared loading 40 nM (corresponding to 0.5 µg/mL) of L3-301 
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siRNA sequence (sense 5’-3’: GGACUCUGAAGAUGUACCU[dT][dT] 21nt, standard 302 
purification, Sigma-Aldrich, UK). Refer to the Supplementary Information for detailed 303 
description of siRNA sequences tested for KRAS silencing (Section SI.2). Briefly, HCT-116 304 
cells were seeded at a density of 10,000 cells/cm2 in TCP 12-well plates with flat bottom 305 
(Thermo Scientific, NUNC MULTIDISH 12, #150628) and left adhere overnight. Cells were 306 
then incubated in complete media containing NP (HA-coated) for 48 hours in a humidified 307 
5% (v/v) CO2 air atmosphere at 37°C. In the case of Nanocin NP, the media was changed 308 
after 24 hours, which has been found to improve the silencing efficiencies. Nanocin is 309 
compatible with repeat transfection due to relatively low cell toxicity. LipofectamineTM 2000 310 
was used as control. NP containing media were removed and cells thorough rinsed with PBS 311 
(n=3). The total RNA was extracted using phenol-chloroform method with: TRI Reagent 312 
(Cat. No.: T9424, Sigma-Aldrich). Reverse Transcription Reaction was performed using kit: 313 
High Capacity RNA-to-cDNA kit, Applied Biosystems and finally amplification (qPCR) was 314 
performed using kit: 2xqPCRBIO SyGreen Mix Lo-ROX (Cat.No. PB20.11-05, Applied 315 
Biosystems, UK) following manufacturer’s instructions. 316 
2.8 Statistical Analysis 317 
Differences between groups were considered to be significant at a P value of <0.05. Statistical 318 
analyses (One-way ANOVA) were performed with GraphPad Prism 7.0 (GraphPad Software, 319 
Inc., San Diego, CA).  320 
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3. Results and Discussion 321 
3.1 Nanoparticles characterization  322 
3.1.1 Nanoparticle physical stability. As prepared, all NP showed a rather comparable 323 
hydrodynamic size, although typically lower for Nanocin (Table 1, Figure 1a and 1b). This is 324 
likely due to the higher charge density of this polymer, which allows a higher ionic cross-link 325 
density and therefore also a lower water content in the particles. As expected, the ζ-potential 326 
(surface charge) depended on the polycation:HA weight ratio, and shifted from positive to 327 
negative values with increasing HA content. With both polycations, a ‘charge inversion’ 328 
occurred at a polycation:HA weight ratio between 1:1 and 1:2; these samples also exhibited 329 
the largest sizes. At stoichiometry ratios close to the effective complexation between positive 330 
and negative charges, polyelectrolyte complexes form and keep aggregating due to the 331 
reduced repulsion, until a size is reached. At this equilibrium, a small imbalance in either of 332 
the charged components leads to a sufficient surface coverage to grant electrostatic 333 
stabilization. In deionized water, chitosan-based NP showed a mild agglomeration upon 334 
storage (size variation less than 5%), independent of the amount of HA. On the contrary, 335 
Nanocin stability depended on HA: Better stability at high HA content which decreased at 336 
low (polycation:HA < 1:2), and showed significant increases in size and ζ-potential post 337 
storage. This effect is probably due to the strong interactions between the high-cationic 338 
density, small-size Nanocin and HA, which significantly reduce the electrostatic stabilization 339 
due to excess (uncomplexed) negative charges of HA. Due to their better stability, all further 340 
experiments were conducted with a 1:4 polycation/HA ratio. 341 
 
Table 1. Effect of storage in water on the size and charge of nanoparticles with variable polycation:HA weight 
ratio. 
Polycation:HA a 
(weight ratio) 
 Size (nm) b  ζ-potential (mV) b 
 As prepared Stored c  As prepared Stored c 
        
1:0 chitosan  210 ± 5 210 ± 5  52.0 ± 1.5 52.0 ± 1.0 Nanocin  120 ± 10 390 ± 100  15.5 ± 7.5 24.0 ± 0.5 
        
1:1 chitosan  270 ± 10 300 ± 15  35.0 ± 1.0 35.0 ± 1.0 Nanocin  170 ± 10 400 ± 10  21.0 ± 1.0 23.0 ± 1.0 
        
1:2 chitosan  220 ± 5 205 ± 5  -25.5 ± 0.5 -24.5 ± 1.0 Nanocin  210 ± 75 320 ± 10  -19.0 ± 1.5 -21.0 ± 0.5 
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1:3 chitosan  230 ± 5 255 ± 15  -31.0 ± 1.0 -32.5 ± 1.0 Nanocin  180 ± 20 185 ± 5  -30.0 ± 0.5 -31.5 ± 0.5 
        
1:4 chitosan  275 ± 5 280 ± 5  -34.5 ± 0.5 -35.0 ± 1.0 Nanocin  160 ± 10 170 ± 5  -30.0 ± 1.0 -30.5 ± 1.0 
a Please note that siRNA was always used at a ratio 2.3%wt. in respect to the polycation weight, hence nanoparticles were 
prepared also in the absence of HA. 
b Concentration: 1 mg/mL in deionized water 
c Storage: 1 week, 4°C in deionized water. 
 
3.1.2 Protection of siRNA against RNase. We have assessed the stability of siRNA in 342 
nanoparticles (siRNA:polycation 1:4 weight ratio), when they were exposed to different 343 
concentrations of RNase I (Figure 1e). siRNA in solution was already partially degraded at 344 
0.01 U/μL RNase (~10% degradation), with >50% degradation at 0.1 U/μL RNase, whereas 345 
siRNA liberated from nanoparticles was intact even after exposure to 1 U/μL RNase, with no 346 
statistically relevant difference with the two polycations and with/out HA.  347 
 348 
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Figure 1. Physico-chemical characterization of nanoparticles. Z-average size (histogram) and ζ-potential (red 
dots) of as-prepared Nanocin- (a) and chitosan-based (b) nanoparticles. The effect of storage is respectively 
shown in (c) and (d) for particles without HA and a 1:4 polycation:HA ratio. A typical PAGE gel analysis (e) 
shows payload protection for 25% wt. siRNA-loaded nanoparticles after incubation with different concentrations 
of RNase I (for each column, from left to right: 0, 0.01, 0.1, 1 U/μL). Recovered siRNA is expressed as percentage 
with respect to its control, each value is reported as average ± st.dev. of at least three independent samples. 
3.2 Targeting and internalization of HA-coated nanoparticles 349 
3.2.1 CD44 expression. Colorectal cancers have a high incidence of mutation of KRAS, and 350 
we have therefore chosen a model of human colorectal cancer, HCT-116 cells, known to 351 
present KRASG13D mutation (Alves et al., 2015). HCT-116 also have high CD44 expression 352 
(Rios de la Rosa et al., 2017b), and unsurprisingly this is higher than in the cells (HDFa) 353 
which we used as a model for stromal component of the tumor microenvironment (Figure 2a). 354 
Importantly, HCT-116 cells were positive to CD44 variants commonly associated to 355 
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malignancies, such as CD44v3high (Figure 2c) and CD44v6 high (Figure 2e), but not CD44v4 356 
(Figure 2d). No CD44 variants were detected in HDFa (data not shown). 357 
 
 
Figure 2. Characterization of CD44 expression in the selected cellular models. a) Flow cytometry measurements 
of total CD44 (all isoforms combined) in HCT-116 and HDFa. Results are expressed as mean ± st.dev. (n=3, 
N=2). Immunofluorescence (IF) cancer cells (HCT-116) stained for: b) total CD44, c) CD44v3, c) CD44v4 and e) 
CD44v6. Scale bars 50 μm. 
3.2.2 Nanoparticle internalization: mono-culture vs. co-culture. We have followed the 358 
kinetics of both NP internalization via flow cytometry using a fluorescently labelled siRNA 359 
(L3-DY547-NP) for 24 h. NP internalization was firstly investigated on cancer cells and 360 
fibroblasts in mono-culture, then cells were co-cultured. In mono-culture of both cell types, 361 
chitosan/HA NP showed a more rapid internalization, however eventually reaching a plateau, 362 
as already seen in previous works (Lallana et al., 2017; Rios de la Rosa et al., 2017a). At the 363 
later time points the fluorescence intensities produced by the siRNA were comparable in both 364 
carriers (Figure 3). Qualitatively, in co-culture we observed a similar kinetic behavior, i.e. an 365 
earlier plateau for chitosan/HA. However, assuming that the siRNA fluorescence always 366 
provides quantitative and comparable estimates of NP internalization, we noticed another 367 
more interesting phenomenon: in mono-culture the uptake in HDFa and HCT-116 appeared to 368 
be comparable (Figure 3a) between the tested NP, whilst in co-culture HCT-116 always 369 
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internalized NP in much larger amounts (Figure 3b). Of note, where internalization in HCT-370 
116 always increased in co-culture, the internalization in HDFa increased for Nanocin/HA 371 
and decreased for chitosan/HA, which means that although this HCT-116/HDFa differential 372 
internalization (and targeting) was clear for both NP, it was much larger with chitosan/HA 373 
systems. Mechanistically, this may be due an increased expression of CD44 and/or its 374 
variants: we have demonstrated that the overall CD44 expression depends on the HCT-116 375 
environment (3D culture increasing it) (Rios De La Rosa et al., 2018), whereas interactions 376 
with cancer associated fibroblasts have been reported to increase CD44v expression in colon 377 
cancer cells (Misra et al., 2011). Therapeutically, this is a very promising result, which 378 
indicates that HA-coated formulations may be able to preferentially target and treat 379 
populations of tumoral cells, thereby effectively reducing potential off-target effects. 380 
Additionally, preliminary toxicology results showed no cytotoxicity (see Supplementary 381 
Information, section SI.10 and Figure 5SI) or increased levels of cellular stress (see 382 
Supplementary Information, section SI.11 and Figure 6SI). These results indicate that both 383 
nanoparticles are suitable for further in vivo studies. 384 
 
 
Figure 3. Kinetics of internalization of HA-coated L3-DY547-NP in CD44-expressing cell lines: cancer (HCT-
116, CD44+, CD44v6high) and fibroblasts (HDF, CD44low). Results are expressed as mean ± st.dev. of 10,000 
events (n=3 independent samples) at each time point. In mono-culture, similar kinetics of uptake are observed in 
both cell lines and for both NP. Whereas, a more tumor-like environment (co-culture of HCT-116 and HDFa) 
promotes a higher internalization of HA-coated NP, with increased uptake in cancer cells rather than fibroblasts 
at each time point (fold increase of 2-3 at the endpoint).  
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3.2.3 Intracellular localization. At a very early time point (1 h), despite the different 385 
internalization kinetics recorded through flow cytometry, chitosan/HA and Nanocin/HA NP 386 
did not showed a markedly different behavior: both of them were internalized in similar 387 
amounts with some, possibly initial signs of colocalization with lysosomal compartments 388 
(Figure 4a). This snapshot evidenced initial NP localization in lysosomes (yellow from 389 
contemporaneous emission of Lysotracker (green, 488nm) and siRNA (red, 561 nm), but also 390 
signs of possible escape (red siRNA signal around or flanking the yellow or green 391 
organelles). At 24 h, the two HA-decorated L3-DY547-NP are internalized/accumulated in 392 
HCT-116 in similar amounts (Figure 4b; n=5 fields of view, average of 150 cells observed for 393 
each treatment), which is broadly in line with the flow cytometry results. Of note, the siRNA 394 
cytosolic distribution seemed to be consistently more homogeneous with chitosan/HA NP, 395 
and more compartmented (visibly brighter spots) with Nanocin/HA NP. This phenomenon 396 
may indicate a possibly lower availability of siRNA in the Nanocin/HA at this stage, which 397 
would stem from a tighter complexation of the nucleic acid with the polycation. This tight 398 
interaction would be possibly caused by: a) the higher charge density on Nanocin and b) its 399 
lower size. The higher charge density of the polycation may cause a higher avidity; a more 400 
compact siRNA/polycation complex is possibly obtained with Nanocin (smaller Mw) that has 401 
an easier complexation compared to the larger polyelectrolytes (chitosan, entropic penalty for 402 
surface siRNA/polycation coupling) However, we should also consider that any factor 403 
increasing the complexation strength, such as a high charge density, is not necessarily 404 
detrimental: for example, using chitosan we have recently demonstrated that high density of 405 
amines increased chitosan binding to RNAs, but this effect was most likely overcome by 406 
higher endosomolytic efficiency (Lallana et al., 2017). 407 
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Figure 4. Nanoparticle and siRNA intracellular localization: a) lysosomal escape after 1 h incubation with NP, the  
arrows indicate lysosomes (green), the co-localization of nanoparticles in late endosomes/lysosomes (yellow) and 
released siRNA (red); b) internalization of siRNA in HCT-116 cells after 24 h incubation with NP, notably a 
similar percentage of siRNA was delivered in HCT-116, being 3.35% and 3.55% respectively for Nanocin/HA and 
chitosan/HA NP; a more ‘cloudy’ siRNA signal was observed in HCT-116 cells incubated with chitosan/HA NP, 
compared to a more localized siRNA signal for the Nanocin/HA counterparts. Scale bars: 25 µm. 
3.3 Silencing efficacy: siRNA release from nanoparticles and mRNA-KRAS knock-down 408 
3.3.1 Choice of siRNA. We have first investigated the silencing efficiency of a panel of 409 
different siRNA, employing simple Nanocin/siRNA polyplexes, since their high positive 410 
charge (see Table 1) was supposed to stimulate the highest transfection. The silencing 411 
efficiency was evaluated with qRT-PCR, rather than immunostaining methods, due to its 412 
superior sensitivity; this is critical in KRAS analysis as the level of gene expression is low 413 
and therefore difficult to detect. We eventually selected the 414 
GGACUCUGAAGAUGUACCUAGGUACAUCUUCAGAGUCCs sequence as a promising 415 
and more reproducible candidate for further experiments, after comparison of the silencing 416 
efficiencies of 14 siRNAs targeting different regions within the mRNA sequences (see 417 
Supplementary Information, section SI.2 and Figure 1SI). 418 
 419 
3.3.2. KRAS-silencing. Chitosan/HA NP resulted in KRAS silencing to a level comparable to 420 
the gold standard transfecting agent Lipofectamine (no statistical difference between the two 421 
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treatments at 48 h, Figure 5a); more importantly, the mRNA-KRAS reduction was 422 
approximately 2-fold higher than with Nanocin/HA. As anticipated in section 3.2.3, the 423 
higher charge density of Nanocin may be a limiting factor for siRNA intracellular availability, 424 
which is a possible explanation for its lower silencing activity. Of interest, the HA-decorated 425 
NP caused levels of silencing similar to those of the binary polyplexes, i.e. siRNA/polycation 426 
only (see Supplementary Information, Figure 2SI); the latter are cationic species, and as such 427 
are characterized by an efficient cell adhesion and penetration, therefore it is remarkable that 428 
HA, most likely through its interactions with CD44, allows to overcome the effect of charge 429 
inversion. 430 
 
 
Figure 5. KRAS silencing efficacy of HA-coated NP. Relative KRAS expression and mRNA silencing was 
measured after 48 h treatment in HCT-116 cells with: a) as prepared NP: results show no statistical difference of 
chitosan-nanoparticles with respect to lipofectamine and a significant difference between Nanocin NP and 
lipofectamine (n=5, p<0.0001); b) NP after one-week storage at 4°C generally showed a silencing efficacy similar 
to that of as prepared NP. Data are expressed as percentage with respect to untreated cells and are the average on 
n=3 independent experiments. Lipofectamine was used as control (data not reported); c) NP exposed (incubation 
prior use) to RNase I at different concentrations (0, 0.01, 0.1, 1 U/μL). Data are expressed as percentage with 
respect to untreated cells and are the average on n=3 independent experiments. Lipofectamine was used as control 
(data not reported). 
3.3.3 Effect of storage on silencing efficacy. NP were also stored for 1 week at 4°C in 431 
deionized water before using them in silencing experiments; this storage period caused no 432 
significant alteration in the silencing activity of both NP (Figure 5b). Interestingly, we 433 
observed that without HA (direct complexation between siRNA and polycations) the 434 
chitosan-based NP experienced a significant reduction in silencing performance (from >60% 435 
to about 40%, Supplementary Information Figure SI2), which is likely to ascribe to the low 436 
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degree of protonation of chitosan amines, which eventually allows self-aggregation of the 437 
polymer and physical destabilization of the particles.  438 
 439 
3.3.3 Effect of RNase I exposure on silencing performance. As a last step in the assessment of 440 
NP for in vivo administration, we tested whether siRNA loaded in Nanocin- and chitosan-NP 441 
could preserve its silencing functionality when the NP are exposed to potentially RNA-442 
degrading condition, such as the presence of RNAse. To support our previous demonstration 443 
that the apparent integrity of the loaded siRNA (Figure 1e) ensures the preservation of its 444 
silencing capacity, we further tested the silencing efficiency of both NP after exposure to 445 
different concentration of RNase I (i.e. 0.01, 0.1, 1 U/μL) and compared the results to non-446 
exposed NP (incubated in nuclease free water, control). In these experiments, concentrations 447 
of RNAse up to 1 U/μL did not alter the performance of Nanocin/HA NP, whereas that of 448 
chitosan/HA NP was in part decreased. This can be ascribed to the higher complexation 449 
strength of Nanocin (higher charge density, lower molecular weight), which makes more 450 
difficult for an enzyme to reach its target in the bulk of a particle. Indeed, similar effects can 451 
be seen also for the polycomplexes formed without HA (see Supplementary information, 452 
Figure 3SI).  453 
 
Conclusions 454 
We compared two HA-based polyplex systems for the delivery of siRNA in CD44+ cell lines 455 
(HCT-116 and HDFa), for a perspective KRAS-targeted tumor therapy. Our main findings are 456 
that: a) CD44high/CD44v+ cancer cells (HCT-116) are more active for the internalization of 457 
HA-coated NP than stromal standard CD44+ cells (HDFa), and that this difference amplifies 458 
when cells are co-cultured. This is a very encouraging finding that supports the use of HA for 459 
tumor targeting, with potential low off-target effects; b) the strength of the polyelectrolyte 460 
complexation is an important parameter that carries a delicate balance of favorable and 461 
detrimental effects. The stronger interactions between Nanocin and siRNA (and HA) appear 462 
to negatively affect the silencing efficacy of such NP, possibly due to the lower availability of 463 
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the nucleic acid. On the other hand, they most likely provide a higher stability against 464 
nucleases (and other harmful agents for the nucleic acid). Remarkably, we found that chitosan 465 
NP presented the right compromise between polyplexes stability and avidity/efficiency of 466 
siRNA release, which conferred them a high silencing efficacy comparable to the gold 467 
standard transfecting agent (i.e. Lipofectamine). With this rational, further in vivo studies will 468 
need to demonstrate whether the different complexation also affects the stability of the NP in 469 
the blood stream, and whether the higher silencing capacity of chitosan-based systems can be 470 
confirmed in real tumors. 471 
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